Cargando…

A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall Survival

Background: The objective of this work was to evaluate the relationship between the response rates and median overall survival (OS) in higher-risk myelodysplastic syndrome (HR-MDS) to determine whether response rates could be used as predictors of median OS. Methods: Relevant MDS clinical trials wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurumaddali, Abhinav, Salem, Ahmed Hamed, Agarwal, Suresh K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Short Research Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775690/ https://www.ncbi.nlm.nih.gov/pubmed/31632487 http://dx.doi.org/10.7150/jca.33175

Ejemplares similares

Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials
por: Agarwal, Suresh K., et al.
Publicado: (2017)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Time-dependent endpoints as predictors of overall survival in multiple myeloma
por: Félix, Jorge, et al.
Publicado: (2013)

Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes
por: Sotirova, Tatjana, et al.
Publicado: (2014)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
por: Wang, Yu‐Hung, et al.
Publicado: (2022)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes
por: Maurya, Nehakumari, et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation
por: Tanaka, Kazuhiro, et al.
Publicado: (2020)

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
por: Silverman, LR, et al.
Publicado: (2008)

Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors
por: Ter‐Minassian, Monica, et al.
Publicado: (2017)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
por: Maeda, Hideki, et al.
Publicado: (2021)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
por: Ghali, Fady, et al.
Publicado: (2022)

Interim analysis incorporating short‐ and long‐term binary endpoints
por: Niewczas, Julia, et al.
Publicado: (2019)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
por: Cooper, Katy, et al.
Publicado: (2020)

Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis
por: Shameer, Khader, et al.
Publicado: (2021)

Visual attention is not deployed at the endpoint of averaging saccades
por: Wollenberg, Luca, et al.
Publicado: (2018)

Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes: Results of a meta-analysis of observational studies
por: Pileggi, Claudia, et al.
Publicado: (2017)

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
por: Nie, Run-Cong, et al.
Publicado: (2020)

Hand movements respond to any motion near the endpoint
por: Crowe, Emily M., et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

Short-term effects of pesticide fipronil on behavioral and physiological endpoints of Daphnia magna
por: Bownik, Adam, et al.
Publicado: (2021)

Electrocardiogram in Friedreich's ataxia: A short‐term surrogate endpoint for treatment efficacy
por: Mastroianno, Sandra, et al.
Publicado: (2020)

Short Term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?
por: Owens, Lukas, et al.
Publicado: (2023)

Optimization of the Transwell(®) System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches
por: Amini, Elham, et al.
Publicado: (2021)

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists
por: Methy, Nicolas, et al.
Publicado: (2010)

Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial
por: Chen, Yu-Pei, et al.
Publicado: (2015)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
por: Forsythe, Anna, et al.
Publicado: (2018)

Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
por: Han, Weiming, et al.
Publicado: (2022)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints
por: Zocholl, Dario, et al.
Publicado: (2023)

Can a Short Term of Repeated Ejaculations Affect Seminal Parameters?
por: Mayorga-Torres, Jose Manuel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6es97trj3u3unvbi1vu2e5eu2s